Kotak Alt invests ₹1,445 crore for buying of API arm of Viatris by Matrix Pharma  

Published - June 11, 2024 10:34 pm IST - MUMBAI

Kotak Alternate Asset Managers Ltd. has announced an investment of ₹1,445 crore for acquisition of API business of Viatris by Matrix Pharma Private Ltd. The acquisition has been consummated by the Kotak Strategic Situations Fund II. Post this acquisition, Matrix will gain access to strong R&D capabilities, including over 185 scientists and over 600 DMF filings.  Kotak Alt said it would enable Matrix to consolidate its leadership in the API business by strengthening its third-party sales and will selectively evaluate inorganic opportunities in the pharma contract development and manufacturing organization (CDMO) space.  Srini Sriniwasan, Managing Director, Kotak Alternate Asset Managers said, “This buy-out of a significant business along with key incumbent management coming on board, demonstrates our strong deal sourcing and structuring capabilities.”  “It underscores our Pharma industry capabilities and ability to create a platform to build a robust API business which we can support with organic and inorganic growth.” he added.  

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.